Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shein to increase product testing in response to EU probe

(Sharecast News) - Chinese fast-fashion retailer Shein said it was increasing product testing and set a target of scrutinising 2.5 million products this year in response to pressure from the European Union. The controversial company added that it would spend $15m on compliance initiatives this year after the EU said fake discounts, pressure selling, and other practices breach the bloc's law.

It gave Shein a month to respond to its findings or face fines based on its sales in the EU countries where it says it has breached the law.

Shein, which sells its own-branded clothes in 150 countries, also runs marketplace for sellers of toys, gadgets, and homeware sent directly from factories mostly in China to consumers globally.

Since it launched its marketplace, Shein has stopped working with more than 540 sellers over compliance breaches, the company said in a statement.

The EU's ongoing investigation by its consumer rights arm found "a broad range of practices with which consumers are confronted while shopping on Shein and that are in breach of EU law" including instances of pretending to offer better deals by showing price reductions that were not based on actual prior prices, and fake deadlines to put consumers under pressure to buy.

Shein, which is looking for a stock market flotation was reportedly said to be working towards a Hong Kong listing after its proposed London IPO fell short of getting the green light from the China Securities Regulatory Commission, according to a news agency Reuters which cited unnamed sources.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.